In one of the largest studies of its kind, a team of scientists analyzed cancer risk among 8,000 diabetics treated with the diabetes drug metformin.

Over a 10-year period, they observed a 54% lower incidence of all cancers compared to the general population.

Metformin not only exerted a major protective effect against cancer development, but those who developed cancer exhibited a significantly higher survival rate; including those with malignant cancers of the lung, colon, and breast.

Of equal significance was the finding that the earlier the metformin regimen was initiated, the greater the preventive benefit.

Join Dr. Mike as he shares more information about this potentially life-saving discovery.